Samir Parekh, MBBS, a professor of medicine (Hematology and Medical Oncology) and Oncological Sciences at the Icahn School of Medicine at Mount Sinai, discusses the ASH 2025 abstract titled, “Earlier use of ciltacabtagene autoleucel (cilta-cel) is associated with better immune fitness and stronger immune effects as shown by correlative analysis of peripheral blood and the bone marrow tumor microenvironment (TME) from the CARTITUDE-4 study.”
Dr. Parekh explains how a healthier immune system in less-pretreated patients leads to more durable responses with cilta-cel. He also breaks down the science of immune fitness.
